In May 2003, the country’s largest unitary state enterprises producing immunobiological products were united into Scientific and Production Association Microgen. The main objective of NPO Microgen was to create a competitive production unit in the sphere of biotechnologies and to introduce new highly effective preparations in the healthcare practice. The establishment of the production association had a synergistic effect on the whole scientific and production potential of the country in the sphere of immunobiology and allowed separate companies to strengthen their scientific potential, exclude redundant developments and coordinate the production, sales and logistics.
Currently, the Company includes nine branches located throughout the country and employs more than 5 thousand people, including 104 candidates of sciences, 7 doctors of sciences and 3 professors.
The priority area of business is the production of vaccines for dangerous infectious diseases, including the vaccines from the National Calendar of Preventive Vaccination (NCPV). The company’s share in total sales of immunobiological preparations of Russian producers is 43%, net of supplies under the NCPV. The revenues from sale of preparations in 2014 was more than 7 billion rubles.
Some companies included in NPO Microgen have more than 100 years history. They develop and produce vaccines and toxoids, blood products, bacteriophages, diagnostic preparations, growth media and allergens.
Leading production enterprises of NPO Microgen:
9 production sites
11 branches with the management company in Moscow
6200 specialists and employees
53% supplies of all vaccines from the National Calendar of Preventive Vaccination
17% increase in the value of production assets in 2013
7.6 billion rubles in 2014 – revenues of NPO Microgen